Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
To investigate safety and efficacy on Japanese subjects treated with nelarabine injection for intravenous use in clinical settings of the following diseases:

1. T-cell acute lymphocytic leukemia (T-ALL)
2. T-cell lymphoblastic lymphoma (T-LBL) Also, "any adverse events involving neurological disorder, hypotension, and blood disorder and their details" are to be investigated as an item of particular concern. In addition, subject outcome (alive or dead) at one year after the start of treatment will also be investigated.
Cancer
DRUG: Nelarabine
The number of adverse events in Japanese subjects treated with nelarabine based on prescribing information under the conditions of general clinical practice., 1 year|Any incidence of adverse events related to neurological disorder, hypotension, and blood disorder and their details, 1 year
Outcome (alive or dead) at one year after the start of treatment, 1 year
To investigate safety and efficacy on Japanese subjects treated with nelarabine injection for intravenous use in clinical settings of the following diseases:

1. T-cell acute lymphocytic leukemia (T-ALL)
2. T-cell lymphoblastic lymphoma (T-LBL) Also, "any adverse events involving neurological disorder, hypotension, and blood disorder and their details" are to be investigated as an item of particular concern. In addition, subject outcome (alive or dead) at one year after the start of treatment will also be investigated.